- In mid-July 2026, Rambam Health Care Campus, EOS GmbH, and PTC Inc. announced a collaboration to build a Digital Implant Engineering Center in Haifa, integrating metal 3D printing with PTC’s Creo CAD tools to produce customized patient implants at the hospital.
- By pairing point-of-care 3D printing with PTC’s design and validation software, this effort highlights how tightly integrated digital workflows can support highly personalized medical treatments.
- We’ll now explore how initiatives like Onshape Labs’ AI-driven CAD capabilities may influence PTC’s existing investment narrative around AI industrial software.
AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
PTC Investment Narrative Recap
For me, the core PTC thesis is about whether its AI enabled CAD and PLM tools can stay mission critical as manufacturers digitize product design and service. The Rambam collaboration showcases Creo inside a tightly integrated, regulated medical workflow, but it does not appear to change the near term focus on driving ARR growth or the key risk around competition and pricing pressure in core markets.
The recent Onshape Labs announcement feels most relevant here, because it brings AI directly into everyday cloud CAD workflows with features like AI Quick Render and text to CAD tools. If these capabilities gain traction, they could support PTC’s AI industrial software catalyst by deepening usage and reinforcing its position as customers test new, data rich design approaches alongside initiatives such as the Digital Implant Engineering Center.
Yet behind these promising AI stories, investors should still be watching how increasing regulatory and compliance demands might affect PTC’s cost base and pricing power over time...
Read the full narrative on PTC (it's free!)
PTC's narrative projects $3.3 billion revenue and $894.9 million earnings by 2029. This requires 3.5% yearly revenue growth and an earnings decrease of about $305 million from $1.2 billion today.
Uncover how PTC's forecasts yield a $179.25 fair value, a 51% upside to its current price.
Exploring Other Perspectives
Some higher end analysts already expected revenue to reach about US$3.3 billion and earnings around US$809 million, yet they also highlight rising regulatory and compliance burdens that could squeeze margins, so you can see how opinions on PTC’s future are far more optimistic than the consensus and may shift again as healthcare focused projects like Rambam and new AI features in Onshape are digested.
Explore 7 other fair value estimates on PTC - why the stock might be worth just $131.43!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your PTC research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free PTC research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PTC's overall financial health at a glance.
Want Some Alternatives?
Our top stock finds are flying under the radar-for now. Get in early:
- Find 40 companies with promising cash flow potential yet trading below their fair value.
- Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com